{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:20:43Z","timestamp":1786119643586,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1097\/fpc.0b013e32834592fe","type":"journal-article","created":{"date-parts":[[2011,3,16]],"date-time":"2011-03-16T03:22:12Z","timestamp":1300245732000},"page":"365-374","source":"Crossref","is-referenced-by-count":19,"title":["Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab"],"prefix":"10.1097","volume":"21","author":[{"given":"Janet S.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soren","family":"Germer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kenwright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryma","family":"Benayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Spleiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Pilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hemmings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Weinblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Kaplowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Krasnow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210213","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00002018-200730040-00001","article-title":"Drug-induced liver injury.","volume":"30","author":"Abboud","year":"2007","journal-title":"Drug Saf"},{"key":"R2-2-20210213","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","article-title":"Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R3-2-20210213","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study.","volume":"69","author":"Jones","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R4-2-20210213","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1517\/13543780903203789","article-title":"Targeting IL-6 in the treatment of inflammatory and autoimmune diseases.","volume":"18","author":"Ding","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"R5-2-20210213","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd2863","article-title":"Tocilizumab.","volume":"8","author":"Scheinecker","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"R6-2-20210213","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/1098-1004(200010)16:4<297::AID-HUMU2>3.0.CO;2-Z","article-title":"Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosultransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype.","volume":"16","author":"Kadakol","year":"2000","journal-title":"Hum Mutat"},{"key":"R7-2-20210213","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1053\/jhep.2000.18193","article-title":"Molecular diagnosis of a familial nonhemolytic hyperbilirubinemia (Gilberts syndrome) in healthy subjects.","volume":"32","author":"Borlak","year":"2000","journal-title":"Hepatology"},{"key":"R8-2-20210213","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"R9-2-20210213","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R10-2-20210213","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/jhg.2009.31","article-title":"Association study between single-nucleotide polymorphisms in 199 drug-related genes and commonly measured quantitative traits of 752 healthy Japanese subjects.","volume":"54","author":"Saito","year":"2009","journal-title":"J Hum Genet"},{"key":"R12-2-20210213","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","article-title":"Haploview: analysis and visualization of LD and haplotype maps.","volume":"21","author":"Barrett","year":"2005","journal-title":"Bioinformatics"},{"key":"R13-2-20210213","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/ng1847","article-title":"Principal components analysis corrects for stratification in genome-wide association studies.","volume":"38","author":"Price","year":"2006","journal-title":"Nat Genet"},{"key":"R14-2-20210213","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1258\/000456306778520034","article-title":"Gilberts syndrome: an overview for clinical biochemists.","volume":"43","author":"Hirschfield","year":"2006","journal-title":"Ann Clin Biochem"},{"key":"R15-2-20210213","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2217\/14622416.9.6.703","article-title":"Pharmacogenetics of Gilberts syndrome.","volume":"9","author":"Strassburg","year":"2008","journal-title":"Pharmacogenomics"},{"key":"R16-2-20210213","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1101\/gr.229102","article-title":"The human genome browser at UCSC.","volume":"12","author":"Kent","year":"2002","journal-title":"Genome Res"},{"key":"R17-2-20210213","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/GIM.0b013e31818efd77","article-title":"Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan An evidence-based case review.","volume":"11","author":"Palomaki","year":"2009","journal-title":"Genet Med"},{"key":"R18-2-20210213","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.antiviral.2009.09.001","article-title":"Pharmacogenetics of antiretrovirals.","volume":"85","author":"Tozzi","year":"2010","journal-title":"Antiviral Res"},{"key":"R19-2-20210213","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/sj.tpj.6500221","article-title":"A Gilberts syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia.","volume":"4","author":"Danoff","year":"2004","journal-title":"Pharmacogenomics J"},{"key":"R20-2-20210213","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/sj.leu.2404827","article-title":"UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia.","volume":"21","author":"Singer","year":"2007","journal-title":"Leukemia"},{"key":"R21-2-20210213","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.abb.2008.10.003","article-title":"Regulation of gene expression of hepatic drug metabolizing enzymes and transporters by the Toll-like receptor 2 ligand, lipoteichoic acid.","volume":"481","author":"Ghose","year":"2009","journal-title":"Arch Biochem Biophys"},{"key":"R22-2-20210213","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1124\/dmd.108.023630","article-title":"Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6.","volume":"37","author":"Le Vee","year":"2009","journal-title":"Drug Metab Dispos"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01213011-201107000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:49:10Z","timestamp":1786042150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01213011-201107000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0b013e32834592fe","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}